Back to discover
Disease
Leprosy
Late-stage therapeutic developmentEmerging research
2
Publications
11
Clinical trials
2025
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2025-02-18BMJ (Clinical research ed.)
An update on leprosy immunopathogenesis: systematic review.
Research2024-09-06Frontiers in immunology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Results expected Q1 20272026-05-19
Major clinical milestoneImportant
Primary completion2026-06-01
Clinical MilestonesViewHide
Results expected
- 2026-05-19Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 3 StudyResults expected Q1 2027
- 2025-08-07Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in IndonesiaResults expected Q3 2026
Recently completed
- 2026-06-01Monitoring the Effect of Prophylactic Interventions in Contacts of Leprosy Patients Including Field-application of a Novel Immunodiagnostic Test in BangladeshPrimary completion
- 2025-12-10Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical TrialPrimary completion
Activity timeline4
- 2026-06-01ClinicalMonitoring the Effect of Prophylactic Interventions in Contacts of Leprosy Patients Including Field-application of a Novel Immunodiagnostic Test in BangladeshPrimary completion
- 2026-05-19ClinicalBedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 3 StudyResults expected Q1 2027
- 2025-12-10ClinicalRab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical TrialPrimary completion
- 2025-08-07ClinicalEfficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in IndonesiaResults expected Q3 2026
Clinical trials
The current development programme across all trial phases.
Clinical programme
11
4
5
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20242025
Most influential
Major themes5
- Disability-Adjusted Life Years1
- Global Burden of Disease1
- Leprosy1
- Mycobacterium leprae1
- Neglected Diseases1
Leading journals2
- BMJ (Clinical research ed.)1
- Frontiers in immunology1
Leading researchers8
- Alves AK1
- Brasil TP1
- Djirmay AG1
- Dos Santos EC1
- Fall IS1
- Frota CC1
- Li WH1
- Lima KVB1
Affiliations (unnormalised)6
- Evandro Chagas Institute (IEC)1
- Federal University of Ceará (UFC)1
- National Institute of Parasitic Diseases at Chinese Center for Disease Control and Prevention1
- NHC Key Laboratory of Tropical Disease Control1
- One Health Center1
- University of Pará State (UEPA)1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.